To see the other types of publications on this topic, follow the link: Dydrogesteron.
Journal articles on the topic 'Dydrogesteron'
Create a spot-on reference in APA, MLA, Chicago, Harvard, and other styles
Consult the top 50 journal articles for your research on the topic 'Dydrogesteron.'
Next to every source in the list of references, there is an 'Add to bibliography' button. Press on it, and we will generate automatically the bibliographic reference to the chosen work in the citation style you need: APA, MLA, Harvard, Chicago, Vancouver, etc.
You can also download the full text of the academic publication as pdf and read online its abstract whenever available in the metadata.
Browse journal articles on a wide variety of disciplines and organise your bibliography correctly.
1
Repina, M. A., N. E. Lebedeva, L. P. Zdanuk, and A. V. Ivanova. "Progesteron’s agonist Dydrogesteron in the treatment of the miscarriage." Journal of obstetrics and women's diseases 49, no. 1 (2000): 36–38. http://dx.doi.org/10.17816/jowd88936.
Full textAbstract:
The study was earned out to investigate effect of Progesterone 's agonist Dydrogesterone in the treatment оf the miscarriage. Thus, it was seen that Dydrogesterone 's treatment (10 mg/daily per os) zvas more effective than Progesterone for prophylactic miscarriage.
2
Gobrecht-Keller, Ursula. "Gestagengabe in der Menopause: Was sind Unterschiede, Vorteile und Nachteile der einzelnen Präparate?" Journal für Gynäkologische Endokrinologie/Schweiz 24, no. 2 (2021): 58–68. http://dx.doi.org/10.1007/s41975-021-00191-2.
Full textAbstract:
ZusammenfassungFrauen mit intaktem Uterus müssen bei der Anwendung eines systemisch wirksamen Östrogens zur Endometriumprotektion ein Gestagen erhalten. Gestagene lassen sich in verschiedene Wirkstoffgruppen einteilen, welche unterschiedliche Partialwirkungen haben. Dies bedeutet, dass es keinen Klasseneffekt der Gestagene gibt, sondern die Effekte auf Metabolismus sowie auf hormonsensible Gewebe wie Brust, Endometrium und Knochen variieren können. Mikronisiertes Progesteron und Dydrogesteron scheinen in Hinblick auf Herz-Kreislauf-System und Brust die sicherste Option zu sein. Ihre Effekte auf die Glukosehomöostase und den Lipidstoffwechsel sind neutral. Eine menopausale Hormontherapie, einschliesslich der Wahl des Gestagens, sollte immer entsprechend dem Risikoprofil und den Behandlungszielen der Patientin individualisiert werden.
3
Gromova, O. L. "LONG-TERM RESULTS OF NON-ATYPICAL HYPERPLASIA TREATMENT IN PREMENOPAUSAL WOMEN WITH DYDROGESTERON." Bulletin of Problems Biology and Medicine 1, no. 1 (2021): 38. http://dx.doi.org/10.29254/2077-4214-2021-1-159-38-43.
Full text
4
Mueck, Alfred O. "Klinische Beurteilung der Gestagene in der Menopausalen Hormontherapie (MHT)." Therapeutische Umschau 78, no. 8 (2021): 447–55. http://dx.doi.org/10.1024/0040-5930/a001296.
Full textAbstract:
Zusammenfassung. Die primäre Indikation für die Verwendung von Gestagenen in der MHT ist die Vermeidung eines estrogen-bedingten Risikos für ein Endometriumkarzinom. Progesteron hat die geringste endometriale Effektivität, wird jedoch zunehmend (zusammen mit transdermalem Estradiol) eingesetzt, wegen vaskulärer und metabolischer Neutralität und möglicherweise einem geringeren Brustkrebsrisiko. Diesbezüglich weitgehend vergleichbar ist Dydrogesteron, Retroisomer des Progesteron, jedoch mit stärkerer endometrialer Wirksamkeit. Es werden jedoch auch andere Gestagene (inklusive Tibolon) eingesetzt, um androgene, anti-androgene und anti-mineralokortikoide «Partialwirkungen» auszunutzen. Auf Basis der «Women’s Health Initiative»-Studie muss durch die Gestagenkomponente mit einem erhöhten Risiko für Brustkrebs und koronare Herzerkrankungen gerechnet werden. In Beobachtungsstudien wird dies für unterschiedliche Gestagene bestätigt, möglicherweise auch ein durch Gestagen erhöhtes Insultrisiko. Gestagen-bedingte kardiovaskuläre Risiken lassen sich durch einen frühen Behandlungsbeginn mit jeder Form der MHT reduzieren, beziehungsweise kann sogar mit einer Prävention gerechnet werden. Bleibt als wichtigstes Risiko das Brustkrebsrisiko. Da sich dieses mit keiner Form einer MHT ausschliessen lässt, wird vorgeschlagen, künftig ein Screening hinsichtlich bekannter Mechanismen der hormonbedingten Brustkrebsentstehung durchzuführen, zumindest für Patientinnen mit erhöhtem Risiko. Dazu werden neue eigene Forschungsergebnisse beschrieben.
5
Birkhäuser, Martin. "Kurzreview: Internistische Erkrankungen und Menopausale Hormontherapie." Therapeutische Umschau 78, no. 8 (2021): 483–85. http://dx.doi.org/10.1024/0040-5930/a001300.
Full textAbstract:
Zusammenfassung. Postmenopausale Frauen leiden zusätzlich zu klimakterischen Beschwerden oft an internistischen Krankheiten. In diesen Fällen ist es wichtig zu wissen, wann, in welcher Form und in welcher Dosis eine menopausale Hormontherapie (MHT) verordnet werden darf und in welchen Situationen sie kontraindiziert ist. Zur Verminderung des Risikos einer MHT bei internistischen Grundkrankheiten gelten folgende Grundregeln: Sofern keine Kontraindikationen bestehen, soll die MHT innerhalb des «günstigen Fensters» begonnen werden (in einem Alter < 60 Jahren bzw. innerhalb von 10 Jahren ab Menopause). Zu bevorzugen ist eine kontinuierliche transdermale MHT. Ein First-Pass-Effekt ist bei den meisten internistischen Krankheiten unerwünscht. Zudem sollten zyklische Schwankungen der Serumspiegel vermieden und die niedrigste wirksame Dosis verwendet werden: praktisch alle bekannten Nebenwirkungen der MHT sind dosisabhängig. Metabolisch neutrale Gestagene, wie Progesteron, Dydrogesteron und Dienogest, oder transdermales Norethisteron-Azetat (NETA) sind zu bevorzugen, Medroxyprogesteron-Azetat ist hingegen zu vermeiden. Bei Unklarheiten muss das weitere Vorgehen mit dem zuständigen Internisten abgesprochen werden. Angiopathien, z. B. bei Hypertonie, systemischem Lupus erythematodes oder Diabetes mellitus, sind eine absolute Kontraindikation gegen eine MHT. Liegen keine Angiopathien vor, so ist bei diesen Erkrankungen oft eine transdermale MHT nach genauer Nutzen-Risiko-Evaluation und Rücksprache mit dem behandelnden Arzt vertretbar.
6
&NA;. "Dydrogesterone." Reactions Weekly &NA;, no. 1008 (2004): 10. http://dx.doi.org/10.2165/00128415-200410080-00031.
Full text
7
Khanna, Geeta, Madhuri Dabade, Sajal Dutta, et al. "Dydrogesterone usage pattern in India: a knowledge, attitude and practice survey among Indian gynaecologists." International Journal of Reproduction, Contraception, Obstetrics and Gynecology 10, no. 10 (2021): 3793. http://dx.doi.org/10.18203/2320-1770.ijrcog20213839.
Full textAbstract:
Background: There is limited data about the knowledge, perception, and routine clinical usage pattern of dydrogesterone among medical practitioners in India. Therefore, the present survey was undertaken to assess attitudes and perception/practices of obstetrician and gynaecologists towards use of dydrogesterone in the real-life setting.Methods: Total 1168 gynaecologists across India participated in the KAP survey. Sixteen questions which explored indications, dosages, duration, efficacy, tolerability and comparison were asked and results were expressed as percentages.Results: Dydrogesterone has been marketed since the 1960s and has been extensively used worldwide for the treatment of threatened miscarriage (TM) and recurrent miscarriage (RM). Dydrogesterone is approved for hormone replacement therapy (HRT), as well as pregnancy and non-pregnancy-related conditions where there is a progesterone deficiency. In the present survey, dydrogesterone 10 mg twice daily was found to be the most commonly preferred dosage by 823 (73%) gynaecologists. Poor tolerability, compliance and lower efficacy were reported as major limitations of micronized progesterone by 68% of doctors. The average clinical pregnancy rate noted at 12 weeks after Dydrogesterone usage was around 40% by majority of the doctors. However, 30% of doctors noted more than 40% of clinical pregnancy rate after dydrogesterone usage. Almost 35% of doctors reported that the average live birth rate noticed after dydrogesterone usage is around 40%.Conclusions: The present KAP survey highlights that the effectiveness and the tolerability of dydrogesterone is valued by Indian gynaecologists which accounts for its robust clinical utility.
8
&NA;. "Estradiol/dydrogesterone." Drugs & Therapy Perspectives 11, no. 8 (1998): 1–5. http://dx.doi.org/10.2165/00042310-199811080-00001.
Full text
9
Astrakhantseva, M. M., A. I. Myasoutov, L. E. Breusenko, R. I. Shalina, and O. A. Latyshkevich. "Pregnancy loss. Treatment options." Voprosy ginekologii, akušerstva i perinatologii 20, no. 2 (2021): 75–84. http://dx.doi.org/10.20953/1726-1678-2021-2-75-84.
Full textAbstract:
Objective. To justify the selection of the most effective gestagen with an optimal safety profile in the treatment of patients with pregnancy loss. Patients and methods. A retrospective study of 93 records of patients with recurrent pregnancy loss (RPL) who were prescribed gestagens was made. The first group included 49 patients taking dydrogesterone; the second – 44 patients who received micronized progesterone (19 – orally/subgroup 2a/ and 25 – intravaginally/subgroup 2b/). In order to assess the effectiveness of therapy, prolongation of pregnancy up to 22 weeks was the study’s primary endpoint. The secondary endpoint was prolongation of pregnancy up to 34 weeks of gestation and live birth. Results. A positive subjective evaluation was found in 94% of women taking dydrogesterone and in 79.5% of women taking micronized progesterone (68.4% – orally and 88% – intravaginally). The total number of observations with adverse effects when taking dydrogesterone was significantly lower than in case of micronized progesterone: in 7 (16%) and 31 (72%), respectively (p < 0.05). Dull lower abdominal pain was significantly more frequent in oral administration of micronized progesterone compared with dydrogesterone: in 15 (79%) and 11 (22%), respectively (p < 0.05). In dydrogesterone and intravaginal administration of micronized progesterone, pain syndrome occurred with the same frequency. Bloody vaginal discharge was 2.5 times more frequent in group 2: in 4 (8%) patients of group 1 and in 10 (23%) patients in group 2 (p < 0.05). Moreover, bloody discharge remained significantly more often in case of vaginal administration of micronized progesterone (p < 0.05). In oral micronized progesterone, the difference with dydrogesterone was not significant. According to ultrasound data, hematomas that were not accompanied by bloody discharge were registered in 6 (12%) patients taking micronized progesterone, equally for oral and intravaginal administration. Against the background of receiving dydrogesterone, no hematomas were revealed according to ultrasound data. Against the administration of dydrogesterone, both primary and secondary results were achieved in all women. With the use of micronized progesterone, the primary result was achieved in 39 (88.6%), the secondary – in 38 (86%) patients. Early pregnancy loss was in 6 (14%) women of group 2: 5 (11%) had a spontaneous miscarriage before 14 weeks of gestation (intravaginal drug administration), one had premature birth at 32 weeks (oral drug administration). Conclusion. Dydrogesterone has the highest efficacy and optimal safety profile in the treatment of RPL; therefore, it can be considered as the gestagen of choice in early pregnancy. If it is impossible to prescribe dydrogesterone, preference should be given to micronized progesterone – intravaginal route of administration. Key words: dydrogesterone, micronized progesterone, pregnancy loss, progesterone
10
Bergeron, C., та A. Ferenczy. "Безопасностьометрия при непрерывной заместительной гормональной терапии 17b-эстрадиоло-эндопротезной заместительной гормональной терапии 17b-эстрадиолиин иниситисинисисиной". Journal of obstetrics and women's diseases 50, № 3 (2021): 76–82. http://dx.doi.org/10.17816/jowd95597.
Full textAbstract:
The aim of the study was to determine the endometrial safety of oral 17/3- oestradiol combined continuously with dydrogesterone in preventing endometrial proliferation. The low dose group comprised three 52-week (13 cycles of 28 days) studies (two of which were double blind) using a 17ft- о estradiol dose of 1 mg daily combined with dydrogesterone 2,5; 5; 10 or 20 mg daily. The high dose group comprised two 24-week double-blind studies using a 17ft-oestradiol dose of 2 mg daily combined with dydrogesterone 2,5; 5; 10 or 15 mg daily. Endometrial safety was verified by aspiration endometrial biopsies. Inadequate progestational response was defined as proliferative endometrium, endometrial polyp, hyperplasia and carcinoma. Endometrial protection was achieved with dydrogesterone at doses of 5 mg or higher combined with 1 or 2 mg 17^-oestradiol. So, 5 mg daily dydrogesterone appears to be the lowest effective dose to ensure endometrial safety in a continuous combined regimen with 1 or 2 mg 17p-oestradiol.
11
Pluzhnikova, T. A., E. A. Mikhnina, V. A. Kazantsev, and V. F. Bezhenar. "Miscarriage in patients with chronic endometritis and luteal phase deficiency. Principles of treatment and prevention." Voprosy ginekologii, akušerstva i perinatologii 20, no. 1 (2021): 55–63. http://dx.doi.org/10.20953/1726-1678-2021-1-55-63.
Full textAbstract:
Permanent inflammation of the endometrium against the background of altered vaginal microbiota is accompanied by a violation of cyclic tissue changes. The revealed deficiency of the secretory phase of the cycle was formed independently of the synthesis of progesterone by the corpus luteum and led to impaired embryo implantation and miscarriage. Objective. To evaluate the efficiency of dydrogesterone in miscarriage in patients with chronic endometritis (CE) with luteal phase deficiency. Patients and methods. The study involved 127 women aged 25 to 40 years non-pregnant and during pregnancy with biopsyverified deficiency of the luteal phase of the cycle and CE of varying degrees of activity according to immunohistochemistry data. Women from group 1 (n = 83) continuously received dydrogesterone in a cyclic regimen from the moment of diagnosis until the 21st week of pregnancy; women from group 2 (n = 44) received dydrogesterone for 4 months of CE treatment, then it was discontinued and resumed again from the onset of pregnancy until the 21st week. Conclusion. There was no normalization of the structure of the endometrium after CE treatment with dydrogesterone removal from therapy in women with miscarriage and deficiency of the luteal phase of the cycle. Administration of dydrogesterone in a cyclic regimen with pregravid preparation before pregnancy, regardless of the initial level of progesterone in the blood, by women with miscarriage, CE and luteal phase deficiency contributes to normalization of morphological state of the endometrium in most patients, to significant decrease in the frequency of early miscarriage and duration of in-patient treatment, in contrast to women who canceled dydrogesterone. Key words: dydrogesterone, luteal phase deficiency, recurrent miscarriage, chronic endometritis
12
Bespalova, O. N., M. G. Butenko, M. O. Bakleycheva, O. V. Kosyakova, G. S. Sargsyan, and I. Yu Kogan. "Efficacy of progestogens in the management of threatened miscarriage in women with multiple pregnancies resulting from assisted reproductive technologies." Voprosy ginekologii, akušerstva i perinatologii 20, no. 1 (2021): 47–54. http://dx.doi.org/10.20953/1726-1678-2021-1-47-54.
Full textAbstract:
Women with multiple pregnancies resulting from assisted reproductive technologies (ART) demonstrate higher incidence of miscarriage and obstetric complications than women in the general population. Gestagens are the mandatory therapy to prevent miscarriage in women with single pregnancies (level B evidence). Objective. To evaluate the efficacy of different progestogens (dydrogesterone and micronized progesterone) for the treatment of threatened miscarriage in women with multiple pregnancies resulting from ART. Patients and methods. This prospective cohort study included 75 women with multiple pregnancies resulting from ART and threatened miscarriage in the first trimester. Group 1 comprised 46 patients who received oral dydrogesterone at a dose of 40 mg/day. Group 2 comprised 29 patients who received oral micronized progesterone at a dose of 600 mg/day. In both groups, the symptoms of threatened miscarriage were eliminated within 2 weeks. All patients gave their informed consent for long-term supportive therapy with progesterone agents (dydrogesterone at a dose of 20 mg/day and micronized progesterone at a dose of 200 mg/day) up to 26 weeks of gestation without interruptions. Results. Treatment of threatened miscarriage in the first trimester using progestogens was effective in 93.6% of patients from both groups. Patients receiving progesterone developed cervical shortening twice as often as patients receiving dydrogesterone (55.2% vs 26.1%). Patients receiving vaginal progesterone were 4 times more likely to have bacterial vaginosis. Conclusion. Administration of dydrogesterone and micronized progesterone as a part of comprehensive treatment to prevent miscarriage in the first trimester with subsequent progestogen support up to 26 weeks of gestation was highly effective. Dydrogesterone was significantly more effective in prevention of obstetric complications. Key words: multiple pregnancy, assisted reproductive technologies, pregnancy after ART, posttransfer support, threatened early miscarriage, cervical weakness, dydrogesterone, micronized progesterone
13
Gabidullina, Rushania I., Ekaterina A. Koshelnikova, Tatiana N. Shigabutdinova, Evgenii A. Melnikov, Gulfiria N. Kalimullina, and Angelina I. Kuptsova. "Endometriosis: impact on fertility and pregnancy outcomes." Gynecology 23, no. 1 (2021): 12–17. http://dx.doi.org/10.26442/20795696.2021.1.200477.
Full textAbstract:
Aim. To investigate the modern condition of the problem of infertility and obstetric complications in endometriosis and the main management aspects of women with endometriosis in pregnancy planning.
 Materials and methods. The article presents a systematic literature review on the results of search for studies in electronic databases MEDLINE, PubMed, EMBASE, Cochrane Library and eLibrary.
 Results. Endometriosis is one of the most common causes of infertility. A cascade of adverse reactions caused by endometriosis prevents a successful pregnancy. Currently, there is an evidence that patients with endometriosis have a high risk of several obstetric complications, such as spontaneous miscarriage, premature birth, preeclampsia, low birth weight and gestational diabetes. Progestogens belong to the first line of therapy of endometriosis, and dydrogesterone is a drug that meets all the necessary requirements. The use of dydrogesterone in the treatment of endometriosis helps to reduce the negative symptoms of endometriosis, improve the quality of life and increase fertility. Dydrogesterone is the only progestogen that has two effective regimens for endometriosis, which allows prescribing therapy for women who are planning pregnancy and for those who have already realized their reproductive plans. Dydrogesterone is the only progestogen that has been suggested to increase the chances of pregnancy in women with endometriosis. Dydrogesterone has been shown to be effective in supporting the luteal phase in ART programs, treating threatening and recurrent miscarriages.
 Conclusion. Endometriosis is associated with infertility and a high risk of obstetric complications. Dydrogesterone has a number of advantages compared to other progestogens.
14
Kalinka, Jaroslaw, and Julia Szekeres-Bartho. "Effect of dydrogesterone on the hormonal profile and concentration of progesterone-induced blocking factor in pregnant women with threatened abortion." Journal of obstetrics and women's diseases 54, no. 1 (2005): 96–102. http://dx.doi.org/10.17816/jowd81599.
Full textAbstract:
Problem: The therapeutic value of progestogens in threatened abortion is still under debate. In the presence of sufficient progesterone levels during pregnancy, lymphocytes synthesize a mediator [progesterone-induced blocking factor (PIBF)] that is anti-abortive in mice. The aim of this study was to evaluate the effect of dydrogesterone on pregnancy outcome of threatened aborters.
 Method of study: Twenty-seven threatened aborters were treated for 10 days with dydrogesterone (30-40 mg/day). Sixteen healthy pregnant controls received no treatment. Serum progesterone and estradiol concentrations as well as urine PIBF concentrations were measured by enzyme-linked immunosorbent assay (ELISA).
 Results: Pregnancy outcomes in dydrogesterone-treated threatened aborters did not statistically differ from those in healthy controls. Serum progesterone concentrations in control patients, but not those in threatened aborters increased as pregnancy progressed. Following dydrogesterone treatment, initially low PIBF concentrations of threatened aborters significantly increased (P = 0,001) to reach the PIBF level found in healthy controls.
15
Foster, Rachel H., and Julia A. Balfour. "Estradiol and Dydrogesterone." Drugs & Aging 11, no. 4 (1997): 309–32. http://dx.doi.org/10.2165/00002512-199711040-00006.
Full text
16
Spark, M. Joy. "Is dydrogesterone progesterone?" Journal of Reproductive Immunology 95, no. 1-2 (2012): 101. http://dx.doi.org/10.1016/j.jri.2012.04.006.
Full text
17
Tskhay, V. B., and A. E. Schindler. "New options for preeclampsia prevention." Voprosy ginekologii, akušerstva i perinatologii 20, no. 4 (2021): 123–30. http://dx.doi.org/10.20953/1726-1678-2021-4-123-130.
Full textAbstract:
The analysis of literature data on the role of placenta disorders in the development of preeclampsia (PE) was performed according to Pubmed and eLibrary updates. Although a complete understanding of the pathogenesis of PE remains unclear, the placenta theory was found as one of the principal ones. The appropriateness of prescribing progestogens for the prevention of PE is the subject of an actual debate. Based on the results of our own research, there was demonstrated the efficacy in the preventative prescription of dydrogesterone (at a dose of 30 mg/day) from early periods to 20 weeks of gestation in pregnant women with high-risk factors. The rescription of dydrogesterone contributed to a statistically significant reduction in this pregnancy complication (13.1 and 71/4%, p < 0,001).It was found that women taking dydrogesterone significantly less developed such disorders as arterial hypertension (3.2 and 71.2%, p < 0.001), proteinuria (0 and 66.18%, p < 0.001), fetal growth restriction (2.2 and 21.58%, p < 0.001), uteroplacental vascular insufficiency (3.2 and 21.58%, p < 0.001), and preterm birth (8.6 and 53.95%, p < 0.001). Conclusion. The importance of the placental factor in the pathogenesis of PE, the prescription of progestogens corresponds to the main principle of pathogenetic prevention of this complication. Administration of dydrogesterone in the first and second trimesters (6 to 20 weeks of pregnancy) significantly reduces the incidence of PE in high-risk pregnant women. Key words: preeclampsia, prevention, high-risk groups, progestogens, dydrogesterone
18
Lee, Hee Joong, Tae Chul Park, Jae Hoon Kim, Errol Norwitz, and Banghyun Lee. "The Influence of Oral Dydrogesterone and Vaginal Progesterone on Threatened Abortion: A Systematic Review and Meta-Analysis." BioMed Research International 2017 (2017): 1–10. http://dx.doi.org/10.1155/2017/3616875.
Full textAbstract:
Objective. To conduct systematic analyses to evaluate the efficacy of progesterone therapy for the prevention of miscarriages in pregnant women experiencing threatened abortion. Methods. In November 2016, we performed a systematic literature search and identified 51 articles in PubMed, Embase, and Cochrane databases. We identified nine randomized trials that included 913 pregnant women (including 322 treated with oral dydrogesterone, 213 treated with vaginal progesterone, and 378 control subjects) who met the selection criteria. Results. The incidence of miscarriage was significantly lower in the total progesterone group than in the control group (13.0% versus 21.7%; odds ratio, 0.53; 95% confidence interval (CI), 0.36 to 0.78; P=0.001; I2, 0%). Moreover, the incidence of miscarriage was significantly lower in the oral dydrogesterone group than in the control group (11.7% versus 22.6%; odds ratio, 0.43; 95% CI, 0.26 to 0.71; P=0.001; I2, 0%) and was lower in the vaginal progesterone group than in the control group, although this difference was nonsignificant (15.4% versus 20.3%; odds ratio, 0.72; 95% CI, 0.39 to 1.34; P=0.30; I2, 0%). However, the incidence of miscarriage was not different between the oral dydrogesterone and vaginal progesterone groups. Conclusion. Progesterone therapy, especially oral dydrogesterone, can effectively prevent miscarriage in pregnant women experiencing threatened abortion.
19
Schindler, Adolf E. "Dydrogesterone—A unique progestogen." Maturitas 65 (December 2009): S1. http://dx.doi.org/10.1016/j.maturitas.2009.09.002.
Full text
20
Saha, Eti, Fouzia Begum, and Zannatul Ferdous Jesmin. "Role of human chorionic gonadotrophin to prevent repeated early pregnancy loss." Bangladesh Medical Journal Khulna 48, no. 1-2 (2016): 7–10. http://dx.doi.org/10.3329/bmjk.v48i1-2.27090.
Full textAbstract:
Early pregnancy loss is a frustrating experience for both the patient and the physician. Approximately 5% of couples trying to conceive have 2 consecutive miscarriages and approximately 1% couples have 3 or more consecutive losses. Objective of this study is to determine whether therapy with dydrogesterone or Human chorionic Gonadotrophin hormone (HCG) in history of repeated pregnancy loss during the first trimester of pregnancy will improve pregnancy outcome. This is a prospective open comparative study.Women having early pregnancy presenting to a private clinic with history of early pregnancy loss, having no medical disorder were included in this study. Eligible subjects were randomised to receive either dydrogesterone 20mg daily or injection Human Chorionic Gonadotrophins (HCG) 5000 iu intramuscularly at 72 hours interval up to fourteen weeks of pregnancy or no additional treatment. Follow up of those patients were done with transabdominal ultrasonography. Hundred women were recruited. There was no statistically significant difference between the three groups with regard to pretreatment status. The continuing pregnancy success rate was higher in women treated with dydrogesterone (79.17%) and highest with Injection Human Chorionic, Gonadotrophin (86.36%) compared with women received no treatment (70%), (p=0.358). Hormonal support with either dydrogesterone or Human Chorionic Gonadotrophin may increase the chances of a successful pregnancy in women with a history of spontaneous abortion.Bang Med J (Khulna) 2015; 48 : 7-10
21
Pant, P. R., Uma Shrivastava, Sabina Simkhada, et al. "Luteal Phase Defect (LPD): A necessary tool in assisted reproductive techniques." Indian Journal of Obstetrics and Gynecology Research 8, no. 1 (2021): 1–9. http://dx.doi.org/10.18231/j.ijogr.2021.001.
Full textAbstract:
In Luteal Phase Defect (LPD), endogenous progesterone is insufficient to maintain a functional secretory endometrium and also inhibit embryo growth and implant. In 1960, it was estimated that 20 million pregnancies were exposed to Dydrogesterone in utero. LOTUS I and LOTUS II two major multicenter Phase III studies were conducted on patients who were planning to undergo Fertilization (IVF) with or without Intracytoplasmic Sperm Injection (ICSI). The result of both studies shows that Dydrogesterone was non-inferior to micronized vaginal progesterone, which was the presence of fetal heartbeats at 12 weeks of gestation. Progesterone which can be administered either by oral preparation, vaginal administration along with optimal use of estrogen and Gonadotropin-Releasing Hormon (GnRH) agonist drugs is used in the treatment of LPD. Studies have suggested the use of Dydrogesterone in fresh IVF cycles and Luteal Phase Support (LPS) is continued till 10–12 weeks. However, it may be stopped at the time of β-hCG becoming positive or visualization of a fetal heartbeat.
22
Vuong, Lan N., Toan D. Pham, Khanh T. Q. Le, et al. "Micronized progesterone plus dydrogesterone versus micronized progesterone alone for luteal phase support in frozen-thawed cycles (MIDRONE): a prospective cohort study." Human Reproduction 36, no. 7 (2021): 1821–31. http://dx.doi.org/10.1093/humrep/deab093.
Full textAbstract:
Abstract STUDY QUESTION Does the addition of oral dydrogesterone to vaginal progesterone as luteal phase support improve pregnancy outcomes during frozen embryo transfer (FET) cycles compared with vaginal progesterone alone? SUMMARY ANSWER Luteal phase support with oral dydrogesterone added to vaginal progesterone had a higher live birth rate and lower miscarriage rate compared with vaginal progesterone alone. WHAT IS KNOWN ALREADY Progesterone is an important hormone that triggers secretory transformation of the endometrium to allow implantation of the embryo. During IVF, exogenous progesterone is administered for luteal phase support. However, there is wide inter-individual variation in absorption of progesterone via the vaginal wall. Oral dydrogesterone is effective and well tolerated when used to provide luteal phase support after fresh embryo transfer. However, there are currently no data on the effectiveness of luteal phase support with the combination of dydrogesterone with vaginal micronized progesterone compared with vaginal micronized progesterone after FET. STUDY DESIGN, SIZE, DURATION Prospective cohort study conducted at an academic infertility center in Vietnam from 26 June 2019 to 30 March 2020. PARTICIPANTS/MATERIALS, SETTING, METHODS We studied 1364 women undergoing IVF with FET. Luteal support was started when endometrial thickness reached ≥8 mm. The luteal support regimen was either vaginal micronized progesterone 400 mg twice daily plus oral dydrogesterone 10 mg twice daily (second part of the study) or vaginal micronized progesterone 400 mg twice daily (first 4 months of the study). In women with a positive pregnancy test, the appropriate luteal phase support regimen was continued until 7 weeks’ gestation. The primary endpoint was live birth after the first FET of the started cycle, with miscarriage &lt;12 weeks as one of the secondary endpoints. MAIN RESULTS AND THE ROLE OF CHANCE The vaginal progesterone + dydrogesterone group and vaginal progesterone groups included 732 and 632 participants, respectively. Live birth rates were 46.3% versus 41.3%, respectively (rate ratio [RR] 1.12, 95% CI 0.99–1.27, P = 0.06; multivariate analysis RR 1.30 (95% CI 1.01–1.68), P = 0.042), with a statistically significant lower rate of miscarriage at &lt;12 weeks in the progesterone + dydrogesterone versus progesterone group (3.4% versus 6.6%; RR 0.51, 95% CI 0.32–0.83; P = 0.009). Birth weight of both singletons (2971.0 ± 628.4 versus 3118.8 ± 559.2 g; P = 0.004) and twins (2175.5 ± 494.8 versus 2494.2 ± 584.7; P = 0.002) was significantly lower in the progesterone plus dydrogesterone versus progesterone group. LIMITATIONS, REASONS FOR CAUTION The main limitations of the study were the open-label design and the non-randomized nature of the sequential administration of study treatments. However, our systematic comparison of the two strategies was able to be performed much more rapidly than a conventional randomized controlled trial. In addition, the single ethnicity population limits external generalizability. WIDER IMPLICATIONS OF THE FINDINGS Our findings study suggest a role for oral dydrogesterone in addition to vaginal progesterone as luteal phase support in FET cycles to reduce the miscarriage rate and improve the live birth rate. Carefully planned prospective cohort studies with limited bias could be used as an alternative to randomized controlled clinical trials to inform clinical practice. STUDY FUNDING/COMPETING INTERESTS This study received no external funding. LNV has received speaker and conference fees from Merck, grant, speaker and conference fees from Merck Sharpe and Dohme, and speaker, conference and scientific board fees from Ferring; TMH has received speaker fees from Merck, Merck Sharp and Dohme, and Ferring; R.J.N. has received scientific board fees from Ferring and receives grant funding from the National Health and Medical Research Council (NHMRC) of Australia; BWM has acted as a paid consultant to Merck, ObsEva and Guerbet, and is the recipient of grant money from an NHMRC Investigator Grant. TRIAL REGISTRATION NUMBER NCT0399876.
23
Panevina, A. S., N. S. Smetneva, A. M. Vasilenko, and M. V. Shestakova. "The effects of menopausal hormone therapy on proinflammatory cytokines and immunoglobulins in perimenopausal patients with type 2 diabetes mellitus and chronic obstructive pulmonary disease (COPD)." Terapevticheskii arkhiv 90, no. 10 (2018): 79–83. http://dx.doi.org/10.26442/terarkh201890104-83.
Full textAbstract:
Aim. To determine the effects of menopausal hormone therapy dosage on levels of proinflammatory cytokines and immunoglobulins in bodily fluids of patients with type 2 diabetes mellitus (DM) and chronic obstructive pulmonary disease (COPD) during perimenopause. Materials and methods. The study included 119 perimenopausal females with moderate type 2 DM and stable COPD with signs of menopausal syndrome. Cytokine levels in bronchoalveolar lavage fluid and blood serum were measured with flow cytofluorometry (Вeckman Coulter FC500, USA) using a multiplex kit for human cytokines (BMS810FF) in adherence to the manufacturer’s instructions. The lower limit of quantification was 2.5-52.7 pg/mL. The following cytokines were studied: IL-1β, IL-6, IL-8, TNF-α and IF-γ. The data was analyzed with Flow CytomixProver 3.0 manufacturer-licensed software package. IgМ, IgG and IgА in the blood serum (Vektor-Best, Russia) were detected using an immunoenzymatic assay (Stat Fax 3200Analyzer, Awareness Technology, USA). Menopausal hormone therapy (MHT) with 17 beta-estradiol/dydrogesterone (standard - 2 mg, low - 1 mg, ultralow - 0.5 mg): 0.5/2.5 (estradiol 0.5 mg/dydrogesterone 2.5 mg) - ultralow-dose MHT, 1/10 (estradiol 1 mg/dydrogesterone 10 mg) - low-dose MHT; 2/10 (estradiol 2 mg/dydrogesterone 10 mg) - standard-dose MHT. Саrbohydrate metabolism was assessed in three groups. Results and discussion. While 2/10 MHT yielded the most prominent decrease in IL-1β, IL-6, IL-8, TNF-α and IF-γ levels in bronchoalveolar lavage fluid and blood serum, the effect was statistically insignificant compared to 0.5/2.5 and 1/10 MHT. Initially decreased IgM, IgG and IgA levels were elevated in all the three dosage groups with no significant differences between them. As to carbohydrate metabolism target values of glycemia were achieved in all three groups taking MHT. Conclusion. Standard-, low - and ultralow-dose MHT has positive effects on levels of proinflammatory cytokines and immunoglobulins characteristic of the association between type 2 DM, COPD and menopausal syndrome. The differences between the three dosage groups were statistically insignificant. Different dosage of MHT with dydrogesterone provide for improving impaired carbohydrate metabolism.
24
Sampson, Gwyneth A., Patricia R. M. Heathcote, Jennifer Wordsworth, Philip Prescott, and Alan Hodgson. "Premenstrual Syndrome." British Journal of Psychiatry 153, no. 2 (1988): 232–35. http://dx.doi.org/10.1192/bjp.153.2.232.
Full textAbstract:
A double-blind, cross-over, placebo-controlled study of dydrogesterone (10 mg b.d.) in the treatment of premenstrual syndrome is described. Two groups of women were studied: secondarily referred hospital clinic patients, and self-referred patients. Only one-third of patients screened completed the study. All patients showed significant improvements in symptom scores during the course of the study, the only significant difference between placebo- and dydrogesterone-treated patients being an increase in frequency of breast tenderness and a decrease in pain with menstrual bleeding in the latter.
25
Fletcher, C. D., E. Farish, M. M. Dagen, F. Alazzawi, D. McQueen, and D. M. Hart. "The effects of conjugated equine estrogens plus cyclical dydrogesterone on serum lipoproteins and apoproteins in postmenopausal women." Acta Endocrinologica 117, no. 3 (1988): 339–42. http://dx.doi.org/10.1530/acta.0.1170339.
Full textAbstract:
Abstract. erum lipoprotein and apoprotein concentrations were monitored for 24 weeks in 26 postmenopausal women treated with conjugated equine estrogens (0.625 mg/day) with the addition of dydrogesterone (10 mg/day) for the last 12 days of each 28 day cycle. The women had had no previous hormone replacement therapy. The estrogen plus dydrogesterone regimen caused significant (P < 0.05) increases in triacylglycerol and HDL cholesterol concentrations. Both HDL2 and HDL3 cholesterol were increased. There were no other significant changes in lipoprotein concentrations. Both apoprotein AI and apoprotein All concentrations increased significantly (P < 0.05) over the study period. The ratios of apoprotein AI to apoprotein All, apoprotein AI to HDL cholesterol and apoprotein All to HDL cholesterol did not change. At the doses employed in this study, the use of dydrogesterone as a progestogen alters the effects of conjugated equine estrogens on lipoproteins and reinforces the view that the effects of a combined HRT regimen cannot be predicted from a consideration of the effects of the individual components.
26
Mirza, Fadi Ghazi, Ameet Patki, and Claire Pexman-Fieth. "Dydrogesterone use in early pregnancy." Gynecological Endocrinology 32, no. 2 (2016): 97–106. http://dx.doi.org/10.3109/09513590.2015.1121982.
Full text
27
Podzolkova, Podzolkova N. M., Tatarchuk T. F. Tatarchuk, Doshchanova A. M. Doshchanova, Eshimbetova G. Eshimbetova, and Sumyatina L. V. Sumyatina. "Menstrual cycle normalization with dydrogesterone." Akusherstvo i ginekologiia 6_2018 (July 2, 2018): 70–76. http://dx.doi.org/10.18565/aig.2018.6.70-76.
Full text
28
El-Zibdeh, Mazen Y., and Lama T. Yousef. "Dydrogesterone support in threatened miscarriage." Maturitas 65 (December 2009): S43—S46. http://dx.doi.org/10.1016/j.maturitas.2009.11.013.
Full text
29
Pelinescu-Onciul, Dimitrie. "Subchorionic hemorrhage treatment with dydrogesterone." Gynecological Endocrinology 23, sup1 (2007): 77–81. http://dx.doi.org/10.1080/09513590701584741.
Full text
30
Yasin, Asma, Madiha Afzal, and Uzma Aziz. "A Comparison between the Effectiveness of Norethisterone and Dydrogesterone for treatment of Irregular Menstrual Cycle." Pakistan Journal of Medical and Health Sciences 15, no. 11 (2021): 2876–78. http://dx.doi.org/10.53350/pjmhs2115112876.
Full textAbstract:
Background: Abnormal uterine bleeding is defined as irregularities in the menstrual cycle involving frequency, regularity, duration, and volume of flow outside of pregnancy. Up to 1/3rd of women experience abnormal uterine bleeding in their life, with irregularities most commonly occurs at menarche and perimenopause due to disruption of the hypothalamic-pituitary-ovarian axis. Aim: To compare the effectiveness of Norethisterone and Dydrogesterone for the treatment of irregular menstrual cycles due to abnormal uterine bleeding of ovulatory or endometrial dysfunction and to check for patient satisfaction after the use of prescribed hormones by taking their feedback. Methods: This observational, comparative, cohort-prospective study was conducted on 100 nonpregnant women between the ages of 15-45 years who presented with complaints of irregular menstruation in gynae outdoor of AMTH for 6 months from April 2021 to September 2021. After excluding pelvic pathology, known thyroid disease, coagulation disorder, or use of the contraceptive method, the participants were divided into Group A and Group B, each having 50 participants. Results: The mean age±SD of the participants in Group A was 29±3.4 while Group B had mean age±SD was 29.5±3.6. In Group A, 38(76%) patients reported a regular menstrual cycle after 3 months of use while 12(24%) patients complained of persistent irregular menstrual cycle despite 3 months use of Norethisterone with compliance in Group B using Dydrogesterone, 22(44%) patients had regular menstrual cycles while 28(56%) patients had persistent irregular menstrual cycles after three months of use. Conclusion: So we concluded from our study that Norethisterone had a better cycle control than Dydrogesterone. Keywords: Abnormal uterine bleeding of ovulatory and/or endometrial dysfunction, Norethisterone, Dydrogesterone,
31
Иванишкина-Кудина, О. Л., И. В. Иконостасова, and О. В. Коротких. "The Possibility of Using Dydrogesterone in the Complex Treatment of Menstrual Irregularities and Clinical Endometriosis in Women of Early and Young Reproductive Age: Rationale and Prospects for Conservative Therapy." Репродуктивное здоровье. Восточная Европа, no. 4 (November 12, 2021): 487–95. http://dx.doi.org/10.34883/pi.2021.11.4.009.
Full textAbstract:
В обзоре представлены сведения о применении дидрогестерона у женщин раннего репродуктивного возраста с нарушениями менструального цикла и клиническими предикторами и/или проявлениями эндометриоза. Согласно данным, дидрогестерон можно рекомендовать как в режиме монотерапии, так и при комплексном подходе в долибо постоперационном периоде, а также в качестве противорецидивной терапии. Данный терапевтический подход позволяет снизить экономические затраты и максимально сузить зоны риска при гормональной терапии у пациенток с экстрагенитальной патологией и ограниченными диагностическими возможностями в определенный период времени. Длительность терапии дидрогестероном должна составлять не менее 6-9 месяцев для достижения стойкого эффекта. The review provides information on the use of dydrogesterone in women of early reproductive age with menstrual irregularities and clinical predictors and / or manifestations of endometriosis. According to the data, dydrogesterone can be recommended both as a monotherapy and in an integrated approach in the pre-or postoperative period, as well as as anti-relapse therapy. This therapeutic approach allows to reduce economic costs and to maximally narrow the “risk zones” during hormone therapy in patients with extragenital pathology and limited diagnostic capabilities in a certain period of time. The duration of dydrogesterone therapy should be at least 6-9 months to achieve a lasting effect.
32
Kryukov, Evgeniy V., Lyudmila V. Popova, Sergey V. Vasiliev, et al. "Ultra-low dose estradiol plus dydrogesterone: a role in prevention of the development and progression of atherosclerosis." Bulletin of the Russian Military Medical Academy 23, no. 1 (2021): 9–14. http://dx.doi.org/10.17816/brmma63562.
Full textAbstract:
Active development of the "anti-aging medicine", attempts to slow down biological (including vascular) aging led to the creation of new pharmaceuticals including menopausal hormone therapy. The vascular wall protective mechanism of the hormones is not completely clear, but it was shown that natural estrogens are able to control the condition of the vascular wall, prevent platelet adhesion, control a range of metabolic and trophic and energy processes in the endothelium of the vascular wall, producing antithrombogenic factors, namely their inhibition contributes to the development of atherosclerosis. It is known that standard and low-dose estrogen may restore the impaired antithrombogenic potential of the vascular wall, provided its initial reduction does not exceed 20%. The issue of the role and possibilities of correction of the antithrombogenic activity of the vascular wall with ultra-low dose estradiol remained unresolved. As a "clinical model" for the study of this issue, we formed 2 groups of patients: in the study group patients received ultra-low dose estradiol plus dydrogesterone, subjects from the control group received beta-alanine. Three-year follow-up showed a decrease in antithrombogenic activity of the vascular wall in control subjects after 2 and 3 years of follow-up according to the M.V. Baluda's test versus subjects treated with ultra-low dose estrogen plus dydrogesterone. The decrease of the relative risk of reduction of the antithrombogenic activity of the vascular wall with the use of ultra-low dose estrogen plus dydrogesterone during the first two years was 2.3 times, and during the 3 years of follow-up 3.8 times versus control. Thus, prescribing only ultra-low dose estradiol plus dydrogesterone for patients with normal antithrombogenic activity of the vessel wall at baseline reliably lowers the risk of long-term reduction of antithrombogenic potential of the vascular wall.
33
Kronawitter, Desiree, Louis J. Gooren, Hendryk Zollver, et al. "Effects of transdermal testosterone or oral dydrogesterone on hypoactive sexual desire disorder in transsexual women: results of a pilot study." European Journal of Endocrinology 161, no. 2 (2009): 363–68. http://dx.doi.org/10.1530/eje-09-0265.
Full textAbstract:
ObjectiveIt has been reported that hypoactive sexual desire disorder (HSDD) affects one-third of transsexual women (defined as postoperative male-to-female transsexuals) receiving estrogen replacement whose bioavailable androgen levels are lower than in ovulating women and comparable with those in surgically postmenopausal women. The aim of this study was to evaluate the efficacy of transdermal testosterone treatment and of oral dydrogesterone in transsexual women with HSDD receiving estrogens.MethodsSeven transsexual women with HSDD were treated with a testosterone patch and nine transsexual women with HSDD were treated with oral dydrogesterone over 24 weeks. The primary end point was the change in the brief profile of female sexual function (B-PFSF) score. Secondary end points were changes in hormonal parameters and side effect assessments.ResultsA significant increase in total testosterone and free testosterone levels was observed in the group receiving transdermal testosterone. At 24 weeks, there was a significant improvement in the B-PFSF score showing an improvement in sexual desire among transsexual women treated with the testosterone patch, whereas no change in the B-PFSF score was observed in transsexual women treated with oral dydrogesterone. No side effects were reported.ConclusionsIn this pilot study, sexual desire in transsexual women improved significantly after treatment with the testosterone patch, without noticeable side effects.
34
Dutta, Indranil, and Dilip Kumar Dutta. "Management of Luteal Phase Defect in Adolescent Girls." Journal of South Asian Federation of Obstetrics and Gynaecology 4, no. 1 (2012): 10–11. http://dx.doi.org/10.5005/jp-journals-10006-1162.
Full textAbstract:
ABSTRACT Objective To find out the effect of dydrogesterone drug on menstral cycle of adolescent girl. Study design A total of 50 adolescent girl (16-19 years) who were suffering from irregular menstruation were recruited for this study from April 2008 to February 2009, at JNM Hospital, Kalyani, West Bengal, India. Results Menstrul cycle was found to be regular within 6 months of treatment along with the reduction of endometrial thickness. Conclusion Dydrogesterone was found to be safest drug to regularize menstrual cycle of adolescent girl suffering from menstrual irregularity due to luteal phase defect. How to cite this article Dutta DK, Dutta I. Management of Luteal Phase Defect in Adolescent Girls. J South Asian Feder Obst Gynae 2012;4(1):10-11.
35
Omar, M. H., M. K. Mashita, P. S. Lim, and M. A. Jamil. "Dydrogesterone in threatened abortion: Pregnancy outcome." Journal of Steroid Biochemistry and Molecular Biology 97, no. 5 (2005): 421–25. http://dx.doi.org/10.1016/j.jsbmb.2005.08.013.
Full text
36
Hudić, Igor, and Julia Szekeres-Bartho. "Response to letter: Is dydrogesterone progesterone?" Journal of Reproductive Immunology 95, no. 1-2 (2012): 102. http://dx.doi.org/10.1016/j.jri.2012.07.001.
Full text
37
Ioannou, Adam. "Takotsubo cardiomyopathy associated with dydrogesterone use." BMJ Case Reports 14, no. 11 (2021): e246553. http://dx.doi.org/10.1136/bcr-2021-246553.
Full textAbstract:
Takotsubo cardiomyopathy is characterised by left ventricular apical ballooning, in the absence of coronary artery disease, and classically occurs at times of intense stress. Due to the striking preponderance of Takotsubo cardiomyopathy occurring in postmenopausal women, it has been postulated that female sex hormones may also be implicated in its pathogenesis. This case report describes the first case of Takotsubo cardiomyopathy associated with the initiation of dydrogesterone (a synthetic retroprogesterone) in a premenopausal woman.
38
Nosenko, O. M. "Prevention of Great Obstetrical Syndromes in pregnant women with bioavailable progesterone resistance." HEALTH OF WOMAN, no. 2(148) (March 30, 2020): 15–20. http://dx.doi.org/10.15574/hw.2020.148.15.
Full textAbstract:
The article presents modern literature data on the role of defective deep placentation in the development of great obstetrical syndromes, bioavailable progesterone and its receptors in the formation of the placenta and the development of pregnancy, mechanisms of development of resistance to bioavailable progesterone, and a scheme of the pathogenesis of progesterone deficiency during pregnancy as one of the main causes of great obstetrical syndromes. Modern data on the development of resistance to bioavailable progesterone in adolescence, in patients with endometrioid disease, polycystic ovary syndrome and idiopathic recurrent pregnancy loss are presented. The therapeutic possibilities of prophylaxis of great obstetrical syndromes with resistance to bioavailable progesterone are described. Research data on the use of highly selective progestogen with increased affinity for progesterone receptors dydrogesterone for the prevention of great obstetrical in pregnant women with resistance to bioavailable progesterone are presented. Key words: great obstetrical syndromes, defective deep placentation, progesterone, progesterone receptors, bioavailable progesterone resistance, adolescence, endometrioid disease, polycystic ovary syndrome, idiopathic recurrent pregnancy loss, prevention, dydrogesterone.
39
Polushkina, E. S., and R. G. Shmakov. "The role of dydrogesterone in habitual miscarriage." Meditsinskiy sovet = Medical Council, no. 3 (April 17, 2020): 74–77. http://dx.doi.org/10.21518/2079-701x-2020-3-74-77.
Full textAbstract:
Habitual miscarriage is a fairly common complication of early pregnancy. In the opinion of most authors, the term habitual miscarriage is used to describe a loss of two or more pregnancies during the first 22 weeks of pregnancy. Issues of terminology and management continue to be relevant and debatable in medical professional communities and need further discussion. In addition to the medical sides of the issue, habitual miscarriage has a significant psychological impact on women and their partners. Regardless of the gestational age, the loss of pregnancy for most couples is similar in importance to the loss of a newborn and is associated with the loss of hope and plans that future parents connected with a baby who has not yet been born. After repeated losses, bereavement and emotional upheaval are further exacerbated irrespective of the term of abortion. Repeated pregnancy loss is a significant negative event in the life of a couple both from a medical and psychological point of view, that’s why the provision of adequate medical care is one of the objectives of a specialist managing pregnancy. This also involves the choice of effective disease management. Previously it was shown that luteal phase deficiency might be the cause of this phenomenon, and that hormonal deficiency had to be replenished. Many modern publications confirm that progesterone and its derivatives have an important immunomodulatory role in the habitual miscarriage. The article describes the role of progesterone in maintaining pregnancy and the results of studies devoted to the role of dydrogesterone. It also presents data of international studies on the treatment of women with habitual miscarriage.
40
Mueck, Alfred O., Harald Seeger, and Kai-J. Bühling. "Use of dydrogesterone in hormone replacement therapy." Maturitas 65 (December 2009): S51—S60. http://dx.doi.org/10.1016/j.maturitas.2009.09.013.
Full text
41
Pandian, Ramachandhiran Udayar. "Dydrogesterone in threatened miscarriage: A Malaysian experience." Maturitas 65 (December 2009): S47—S50. http://dx.doi.org/10.1016/j.maturitas.2009.11.016.
Full text
42
Seeger, Harald, and Alfred O. Mueck. "Effects of dydrogesterone on the vascular system." Gynecological Endocrinology 23, sup1 (2007): 2–8. http://dx.doi.org/10.1080/09513590701584998.
Full text
43
Roux, C., S. Kolta, C. Chappard, C. Mordieux, M. Dougados, and M. C. de Vernejoul. "Bone effects of dydrogesterone in ovariectomised rat." Osteoporosis International 6, S1 (1996): 225. http://dx.doi.org/10.1007/bf02500438.
Full text
44
Lipatov, Igor' S., Yurii V. Tezikov, Andrei D. Protasov, et al. "Characteristics of early pregnancy and prevention of gestational and perinatal complications in women with metabolic syndrome." Obesity and metabolism 14, no. 4 (2017): 57–66. http://dx.doi.org/10.14341/omet2017457-66.
Full textAbstract:
Introduction. Based on the knowledge of early gestational disorders related to metabolic syndrome (MS), pathogenetically relevant preventive treatment meeting the requirements of perinatal pharmacology can be developed.
 Aim. To reveal clinical and laboratory characteristics of early pregnancy and develop pathogenetically relevant preventive monotherapy for unfavorable gestational and perinatal outcomes in women with metabolic syndrome.
 Material and methods. A total of 230 women were investigated and divided into four groups: Group I consisted of 68 pregnant women with MS who refused any preventive measures; Group II comprised 97 women with MS who received periconceptional preventive monotherapy with dydrogesterone, a progestagen; Group III consisted of 35 healthy primigravidas women with physiological course of gestation; Group IV comprised 30 healthy non-pregnant women. Laboratory testing during IIII trimesters allowed to assess the dynamics demonstrated by markers of lipid spectrum, endothelial dysfunction, apoptosis, decidualization, energy metabolism, and immunomodulation.
 Results. A balance between factors of physiological damage and gestational adaptation in the course of physiological pregnancy has been shown to be of primary significance. In women with MS, embryo-placental dysfunction develops during early pregnancy, and this stage is preceding for major obstetric syndromes. Preventive administration of dydrogesterone in women with MS appeared highly effective: NNT (number needed to treat) was 1.33 (95% CI 0.91.8); OR 5.2 (95% CI 4.65.7).
 Conclusion. Pregestational changes and atherogenic profile of gestational process determine the course of early pregnancy in women with MS with the development of embryo-placental dysfunction and major obstetric syndromes. High efficacy in the prevention of unfavorable gestational and perinatal outcomes was shown by preventive dydrogesterone monotherapy.
45
Lipatov, IS S., YuV V. Tezikov, NV V. Martynova, et al. "UNIVERSAL APPROACH TO THE PREVENTION OF THE SYNDROME OF PATHOLOGICAL PREGNANCY." Science and Innovations in Medicine 2, no. 1 (2017): 13–23. http://dx.doi.org/10.35693/2500-1388-2017-0-1-13-23.
Full textAbstract:
Aim - the purpose of the study is the development of a method for prevention of pathological pregnancy syndrome from the perspective of integral genesis, determined by morphological and functional abnormalities in the fetoplacental system, assessing the effectiveness of methodological standards of evidence-based medicine. Materials and methods. Prospective study of 435 women with high risk of decompensation of placental insufficiency was conducted. Depending on the method of prevention of gestational complications 4 groups were formed: 1st group included 145 pregnant women, who were prescribed dydrogesterone on the 6-20 weeks of gestation, and starting with the 21st week - highly-purified diosmin 600 mg as vasoprotective; in the 2nd group 118 women received a course of preventive treatment with low doses of acetylsalicylic acid; 3rd group included 102 patients who underwent a course of preventive monotherapy with magnesium; 4th group comprised 70 pregnant women who refused preventive treatment. A control group encompassed 30 healthy pregnant women. Dynamic survey included definition of markers of endothelial and hemostasiological dysfunction, vascular-platelet dysfunction elements, apoptosis, inflammatory response, total reactive capacity of the organism, magnesium and carbon dioxide concentrations; a hystostereometric study of placenta was conducted. Standards of evidence-based medicine were applied for the objectification of the effectiveness of the developed method. Results. Method of preventing great obstetric syndromes by successive appointment of progestogen dydrogesterone on the early stage of pregnancy followed by vasoprotective diosmin 600 mg in the 2nd half of pregnancy showed high efficiency (NNT 1.4 (95% CI 1.1 -1.7); OSH 5.3 (95% CI 4.7 -5.8), namely reducing pre-eclampsia by 93%, placental insufficiency with intrauterine growth restriction and/or chronic fetal hypoxia - 95%, preterm birth - 86%, and no premature abruption of normally situated placenta, severe forms of pre-eclampsia and placental insufficiency. Higher clinical effectiveness of the proposed method of prophylaxis of pathological pregnancy syndrome, compared to the use of low-dose acetylsalicylic acid and preparation of magnesium, can be explained by the normalizing effect of dydrogesterone and highly-purified diosmin 600 mg on the immune and biochemical homeostasis, apoptosis and angiogenesis, activation of endothelial and hemostasiological system, adaptive compensatory reactions in the placenta. Conclusion. The method of choice for the prevention of pathological pregnancy syndrome at high risk of fetoplacental system decompensation is the application of progestogen dydrogesterone and vasoprotective diosmin according to the developed method. The study revealed the potential of targeted selection of preventive methods depending on special needs of pregnant women.
46
Solovova, Lilia Dmitriyevna, Olga Igorevna Lineva, Yulia Anatolyevna Artych, Anna Vladimirovna Kazakova, and Inna Alekseyevna Berdnikova. "Retrochorial hematoma: principles of complex therapy." Journal of obstetrics and women's diseases 61, no. 4 (2012): 104–8. http://dx.doi.org/10.17816/jowd614104-108.
Full textAbstract:
In the article there are the hormonal and immunological aspects of pathogenesis retroсhorial hematomas in women with treatened abortion, clinic and diagnosis of this complication. Analysis of efficiency complex therapy with using of Dydrogesterone and Wobenzym were carried out among 80 pregnant women in comparison with standard method of therapy.
47
Hefila, Nermeen M., Tarek A. Karkour, Sara M. Elghareeb, and Tamer M. Abdeldaiem. "Comparative study between vaginal natural progesterone and oral dydrogesterone in prevention of red degeneration of uterine fibroid in pregnancy." International Journal of Reproduction, Contraception, Obstetrics and Gynecology 9, no. 8 (2020): 3330. http://dx.doi.org/10.18203/2320-1770.ijrcog20203318.
Full textAbstract:
Background: Uterine leiomyomas are highly prevalent benign monoclonal tumors, arising from the smooth muscle of the myometrium; they occur in up to 50-60% of reproductive age women, causing significant morbidity in up to 30% of women. The most serious complication of uterine fibroids; is red degeneration that causes severe pain, and may lead to preterm labour, miscarriage, fetal and maternal morbidity and mortality. Objective of this study was designed to compare between the effect of vaginal natural MP and oral dydrogesterone in prevention of red degeneration of uterine fibroid during pregnancy.Methods: Patients were recruited from El-Shatby Maternity University Hospital. They were 50 pregnant females, diagnosed having a uterine fibroid more than 3 cm in size then there were divided into two groups, Group A: twenty-five treated by vaginal natural progesterone, Group B: twenty-five treated by oral dydrogesterone. All patients at 14-15 weeks of gestational age underwent complete history taking, clinical examination and ultrasound examination for mean gestational age and assessment of the type and uterine fibroid.Results: Results showed that there were no statistically significant differences as regards age, obstetric history (gravidity and parity), number, Site, grade and size of the fibroid. There was a significant difference between the two studied groups, regarding the acute abdominal pain, it occurred to only 3 cases (12%) in Group A, versus to 16 cases (64%) in Group B. Regarding occurrence of red degeneration, it occurred only to 3 cases (12%) in Group A, while in Group B it occurred to 15 cases (60%).Conclusions: Vaginal natural micronized progesterone is more effective than oral dydrogesterone in prevention of red degeneration of uterine fibroid in pregnancy with fewer complications. Vaginal natural progesterone daily dose of 200 mg is recommended to all pregnant females with uterine fibroids.
48
Fournier, Agnès, Alban Fabre, Sylvie Mesrine, Marie-Christine Boutron-Ruault, Franco Berrino, and Françoise Clavel-Chapelon. "Use of Different Postmenopausal Hormone Therapies and Risk of Histology- and Hormone Receptor–Defined Invasive Breast Cancer." Journal of Clinical Oncology 26, no. 8 (2008): 1260–68. http://dx.doi.org/10.1200/jco.2007.13.4338.
Full textAbstract:
Purpose We previously found that the risk of invasive breast cancer varied according to the progestagen component of combined postmenopausal hormone therapy (CHT): progesterone, dydrogesterone, or other progestagens. We conducted the present study to assess how these CHTs were associated with histology- and hormone receptor-defined breast cancer. Patients and Methods We used data from the French E3N cohort study, with 80,391 postmenopausal women followed for a mean duration of 8.1 years; 2,265 histologically confirmed invasive breast cancers were identified through biennial self-administered questionnaires completed from 1990 to 2002. The relative risks (RRs) were estimated using Cox proportional hazards models. Results Compared with postmenopausal hormone therapy (HT) never-use, ever-use of estrogen+progesterone was not significantly associated with the risk of any breast cancer subtype, but increasing duration of estrogen+progesterone was associated with increasing risks of lobular (P = .06) and estrogen receptor–positive/progesterone receptor–negative (ER+/PR−; P = .02). Estrogen+dydrogesterone was associated with a significant increase in risk of lobular carcinoma (RR, 1.7; 95% CI, 1.1 to 2.6). Estrogen+other progestagens was associated with significant increases in risk of ductal and lobular carcinomas (RR, 1.6; 95% CI, 1.3 to 1.8; and 2.0; 95% CI, 1.5 to 2.7, respectively), of ER+/PR+ and ER+/PR− carcinomas (RR, 1.8; 95% CI, 1.5 to 2.1; and 2.6; 95% CI, 1.9 to 3.5, respectively), but not of ER−/PR+ or ER−/PR− carcinomas (RR, 1.0; 95% CI, 0.5 to 2.1; and 1.4; 95% CI, 0.9 to 2.0, respectively). Conclusion The increase in risk of breast cancer observed with the use of CHTs other than estrogen+progesterone and estrogen+dydrogesterone seems to apply preferentially to ER+ carcinomas, especially those ER+/PR−, and to affect both ductal and lobular carcinomas.
49
Stevenson, J. С., P. Teter, and В. Lees. "17p-estradiol (1 mg daily) in continuous combination with dydrogesterone (5.10 or 20 mg daily) increases bone mineral density in postmenopausal women." Journal of obstetrics and women's diseases 50, no. 4 (2021): 67–71. http://dx.doi.org/10.17816/jowd95650.
Full textAbstract:
Although the minimal dose of 17/3-estradiol in hormone replacement regimens was originally considered to be 2 mg a day, it is now increasingly accepted that a lower dose of 1 mg a day is effective in protecting women from the detrimental effects of the menopause. A 1-year, multicentre, double-blind, randomized study was conducted in 214 healthy postmenopausal women in order to assess the effect of 17(3-estradiol (1 mg a day) continuously combined with dydrogesterone (5,10 or 20 mg/day) in preventing bone loss. Bone mineral density (BMD) was evaluable in 177 women who completed the study. In all women, a statistically significant increase from baseline in lumbar vertebrae (L.2~L4) BMD was seen after 6 months (+ 2,4%; p0,01); this increase was somewhat greater after 12 months (+ 3,6%;p 0,01). Similar effects were seen in the hip. After 6 months, BMD in the femoral neck, Wards triangle and trochanter had increased by 0,20% (not significant [n.s.]), 0,32% (n.s.)and 1,08% (p0,01), respectively, compared with baseline. Greater increases were again seen after 12 months (+1,16%, + 1,62% and +2,83%, respectively), all of which were statistically significant (p0,01) compared with baseline. The change in BMD from baseline did not diff er significantly between the three dydrogesterone dosages for either L.2~L4 or hip. All dosages were well tolerated and amenorrhoea was achieved in over 70%. In conclusion, 17(3-estradiol (1 mg/day) continuously combined with dydrogesterone (5, 10 or 20 mg/day) results in a significant increase in lumbar vertebrae and hip BMD in postmenopausal women. The lower dose of oestrogen and the avoidance of cyclical bleeding make this a particularly suitable regimen for the prevention and treatment of osteoporosis in older women.
50
El-Zibdeh, M. Y. "Dydrogesterone in the reduction of recurrent spontaneous abortion." Journal of Steroid Biochemistry and Molecular Biology 97, no. 5 (2005): 431–34. http://dx.doi.org/10.1016/j.jsbmb.2005.08.007.
Full text